SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Active, not recruiting · NCT06208748 · Registry updated 2025-10-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2025-10-31 | NCT06208748 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
| Dana-Farber Cancer Institute | 324 |
| Sarcoma Alliance for Research through Collaboration | 7 |
| The Life Raft Group | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Oregon Health & Science University | Portland | United States | 261 |
| Sylvester Comprehensive Cancer Center, University of Miami | Miami | United States | 3 |